Biblio

Found 15 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
L
H. J. Luck, du Bois, A., Weber, B., Pfisterer, J., Goupil, A., Kuhn, W., Barats, J. - C., Blohmer, J. - U., Mousseau, M., Schröder, W., Meier, W., Möbus, V., Richter, B., and Intergroup, A. G. O. - G. I. N. E. C. O., The integration of anthracyclines in the treatment of advanced ovarian cancer, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 34-8, 2001.
A. Lortholary, Largillier, R., Weber, B., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Ann Oncol, vol. 23, pp. 346-52, 2012.
J. F. Liu, Tolaney, S. M., Birrer, M. J., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., Ivy, P., and Matulonis, U. A., A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer, Eur J Cancer, vol. 49, pp. 2972-8, 2013.
R. Lindsay, Paul, J., Siddiqui, N. Ahmad, Davis, J., and Gaffney, D. K., Survey on the management of early cervical cancer among members of the GCIG., Int J Gynecol Cancer, vol. 22, no. 9, p. 1623, 2012.
K. Lindemann, Christensen, R. D., Vergote, I. B., Stuart, G. C. E., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Åvall-Lundqvist, E., Vrdoljak, E., Green, J. A., and Kristensen, G. B., First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG., Ann Oncol, vol. 23, no. 10, pp. 2613-9, 2012.
K. Lim, Small, W., Portelance, L., Creutzberg, C., Jürgenliemk-Schulz, I. M., Mundt, A. J., Mell, L. K., Mayr, N., Viswanathan, A., Jhingran, A., Erickson, B., Santos, J. De Los, Gaffney, D. K., Yashar, C., Beriwal, S., Wolfson, A., Taylor, A., Bosch, W., Naqa, I. El, and Fyles, A., Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer., Int J Radiat Oncol Biol Phys, vol. 79, no. 2, pp. 348-55, 2011.
S. Lheureux, Karakasis, K., Harter, P., Scott, C., Bacon, M., Bryce, J., Le Fur, N., Pujade-Lauraine, E., and Oza, A. M., Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions., Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.
M. M. Leitao, Cheng, X., Hamilton, A. L., Siddiqui, N. Ahmad, Jürgenliemk-Schulz, I. M., Mahner, S., Åvall-Lundqvist, E., Kim, K., and Freyer, G., Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S117-22, 2014.
C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial., Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer., Ann Oncol, vol. 24, no. 4, p. 943, 2013.
C. Khoon Lee, Simes, R. J., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., Bourgeois, H., Högberg, T., Bentley, J., Angleitner-Boubenizek, L., Ferrero, A., Richter, B., Hirte, H., Gebski, V., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer., Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
J. A. Ledermann, Marth, C., Carey, M. S., Birrer, M. J., Bowtell, D. D. L., Kaye, S. B., McNeish, I., Oza, A. M., Scambia, G., Rustin, G. J. S., Stehman, F. B., Gershenson, D., Thomas, G., Berns, E. M. J. J., Casado, A., Ottevanger, N., Hilpert, F., Kim, B. - G., Okamoto, A., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 763-70, 2011.
J. A. Ledermann, Luvero, D., Shafer, A., O'Connor, D., Mangili, G., Friedlander, M. Leonard, Pfisterer, J., Mirza, M. R., Kim, J. - W., Alexandre, J., Oza, A. M., and Brown, J., Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S14-9, 2014.
J. A. Ledermann and Ray-Coquard, I., Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges., Am Soc Clin Oncol Educ Book, pp. e282-6, 2014.